MCM
ZVRA icon

Moore Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Moore Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,563
Closed -$595K – 335
2016
Q1 		$595K Sell
2,563
-562
-18% -$136K 0.02% 207
2015
Q4 		$993K Hold
3,125
– – 0.03% 251
2015
Q3 		$969K Hold
3,125
– – 0.05% 238
2015
Q2 		$919K Buy
+3,125
New +$681K 0.02% 376

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Moore Capital Management's ZVRA Position: Q2 2016 in Review

Moore Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 2,563 shares — an estimated $595K sold.

Moore Capital Management first reported a position in ZVRA in Q2 2015 and held it in 4 quarters. The position peaked at $993K in Q4 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Moore Capital Management reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Moore Capital Management sold 2,563 Zevra Therapeutics shares in Q2 2016, an estimated $595K.
  • Moore Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 4 quarters.
  • Moore Capital Management's Zevra Therapeutics position peaked at $993K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Moore Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.